RaySearch Laboratories AB (CHIX:RAYBS) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
93 GF Score
Price kr234.70
GF Value kr181.40
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB FFO per Share?

FFO per Share only applies to REITs.

CHIX:RAYBS
93GF Score
RaySearch Laboratories AB CHIX:RAYBS
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of kr234.70 is trading 29.4% above its estimated GF Value™ of kr181.40. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for CHIX:RAYBS:

  • FFO per Share:
  • GF Value™: kr181.40 vs. price of kr234.70 (29.4% above fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score

Get the complete analysis for CHIX:RAYBS

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr234.70
Price
kr181.40
GF Value